Literature DB >> 33407452

Profiling the expression of pro-metastatic genes in association with the clinicopathological features of primary breast cancer.

Seyed-Mohammad Mazloomi1, Mitra Foroutan-Ghaznavi2,3,4, Vahid Montazeri5, Gholamreza Tavoosidana6, Ashraf Fakhrjou7, Hojjatollah Nozad-Charoudeh4, Saeed Pirouzpanah8,9,10.   

Abstract

BACKGROUND: Metastasis accounts for ninety percent of breast cancer (BrCa) mortality. Cortactin, Ras homologous gene family member A (RhoA), and Rho-associated kinase (ROCK) raise cellular motility in favor of metastasis. Claudins (CLDN) belong to tight junction integrity and are dysregulated in BrCa. Thus far, epidemiologic evidence regarding the association of different pro-metastatic genes with pathological phenotypes of BrCa is largely inconsistent. This study aimed to determine the possible transcriptional models of pro-metastatic genes incorporate in holding the integrity of epithelial cell-cell junctions (CTTNRhoA, ROCK, CLDN-1, CLDN-2, and CLDN-4), for the first time, in association with clinicopathological features of primary BrCa.
METHODS: In a consecutive case-series design, 206 newly diagnosed non-metastatic eligible BrCa patients with histopathological confirmation (30-65 years) were recruited in Tabriz, Iran (2015-2017). Real-time RT-PCR was used. Then fold changes in the expression of target genes were measured.
RESULTS: ROCK amplification was associated with the involvement of axillary lymph node metastasis (ALNM; ORadj. = 3.05, 95%CI 1.01-9.18). Consistently, inter-correlations of CTTN-ROCK (β = 0.226, P < 0.05) and RhoA-ROCK (β = 0.311, P < 0.01) were determined among patients diagnosed with ALNM+ BrCa. In addition, the overexpression of CLDN-4 was frequently observed in tumors identified by ALNM+ or grade III (P < 0.05). The overexpression of CTTNCLDN-1, and CLDN-4 genes was correlated positively with the extent of tumor size. CTTN overexpression was associated with the increased chance of luminal-A positivity vs. non-luminal-A (ORadj. = 1.96, 95%CI 1.02-3.77). ROCK was also expressed in luminal-B BrCa tumors (P < 0.05). The estrogen receptor-dependent transcriptions were extended to the inter-correlations of RhoA-ROCK (β = 0.280, P < 0.01), ROCK-CLDN-2 (β = 0.267, P < 0.05), and CLDN-1-CLDN-4 (β = 0.451, P < 0.001).
CONCLUSIONS: For the first time, our findings suggested that the inter-correlations of CTTN-ROCK and RhoA-ROCK were significant transcriptional profiles determined in association with ALNM involvement; therefore the overexpression of ROCK may serve as a potential molecular marker for lymphatic metastasis. The provided binary transcriptional profiles need more approvals in different clinical features of BrCa metastasis.

Entities:  

Keywords:  Breast cancer; Claudin; Cortactin; Lymph node; Metastasis; ROCK; RhoA

Year:  2021        PMID: 33407452     DOI: 10.1186/s12935-020-01708-8

Source DB:  PubMed          Journal:  Cancer Cell Int        ISSN: 1475-2867            Impact factor:   5.722


  72 in total

Review 1.  Estrogen signaling: An emanating therapeutic target for breast cancer treatment.

Authors:  Tanmay Saha; Subhajit Makar; Rayala Swetha; Gopichand Gutti; Sushil K Singh
Journal:  Eur J Med Chem       Date:  2019-05-11       Impact factor: 6.514

Review 2.  Digging a little deeper: the stages of invadopodium formation and maturation.

Authors:  Brian T Beaty; John Condeelis
Journal:  Eur J Cell Biol       Date:  2014-07-21       Impact factor: 4.492

Review 3.  Cortactin: a multifunctional regulator of cellular invasiveness.

Authors:  Kellye C Kirkbride; Bong Hwan Sung; Seema Sinha; Alissa M Weaver
Journal:  Cell Adh Migr       Date:  2011-03-01       Impact factor: 3.405

4.  Androgen receptor gene CAG repeat polymorphism and breast cancer risk in Iranian women: a case-control study.

Authors:  Parvin Mehdipour; Saeed Pirouzpanah; Majid Kheirollahi; Morteza Atri
Journal:  Breast J       Date:  2010-12-16       Impact factor: 2.431

5.  Resistin causes G1 arrest in colon cancer cells through upregulation of SOCS3.

Authors:  Snahlata Singh; Surbhi Chouhan; Naoshad Mohammad; Manoj Kumar Bhat
Journal:  FEBS Lett       Date:  2017-05-06       Impact factor: 4.124

6.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

7.  Prognostic implication of CDC25A and cyclin E expression on primary breast cancer patients.

Authors:  Parvin Mehdipour; Saeed Pirouzpanah; Abdolfattah Sarafnejad; Morteza Atri; S Tahereh Shahrestani; Mojgan Haidari
Journal:  Cell Biol Int       Date:  2009-06-23       Impact factor: 3.612

8.  Strategy to enhance efficacy of doxorubicin in solid tumor cells by methyl-β-cyclodextrin: Involvement of p53 and Fas receptor ligand complex.

Authors:  Naoshad Mohammad; Shivendra Vikram Singh; Parmanand Malvi; Balkrishna Chaube; Dipti Athavale; Muralidharan Vanuopadath; Sudarslal Sadasivan Nair; Bipin Nair; Manoj Kumar Bhat
Journal:  Sci Rep       Date:  2015-07-07       Impact factor: 4.379

9.  Cholesterol depletion by methyl-β-cyclodextrin augments tamoxifen induced cell death by enhancing its uptake in melanoma.

Authors:  Naoshad Mohammad; Parmanand Malvi; Avtar Singh Meena; Shivendra Vikram Singh; Balkrishna Chaube; Garikapati Vannuruswamy; Mahesh J Kulkarni; Manoj Kumar Bhat
Journal:  Mol Cancer       Date:  2014-09-01       Impact factor: 27.401

10.  Bitter melon extract inhibits breast cancer growth in preclinical model by inducing autophagic cell death.

Authors:  Naoshad Muhammad; Robert Steele; T Scott Isbell; Nancy Philips; Ratna B Ray
Journal:  Oncotarget       Date:  2017-08-03
View more
  1 in total

1.  Dietary patterns in association with the expression of pro-metastatic genes in primary breast cancer.

Authors:  Mitra Foroutan-Ghaznavi; Seyed-Mohammad Mazloomi; Vahid Montazeri; Saeed Pirouzpanah
Journal:  Eur J Nutr       Date:  2022-04-28       Impact factor: 4.865

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.